Abstract
The objective: comparative evaluation of the efficacy of Glutargine, Erbisol and their co-aplication in patients with psoriatic disease, chronic eczema in the period between exacerbations.Materials and methods. The study involved 185 patients with chronic dermatoses: 110 patients with psoriatic disease and 75 patients with chronic eczema who were treated during the inter-relapsing period. Each of the two patient groups was divided into three subgroups: the first one used Glutargine, the second one Erbisol, and the third one used both. Pharmacotherapeutic efficacy was evaluated by determining the frequency of reactions of oxidative homeostasis (functional compensation, metabolic compensation, and metabolic imbalance) and reactions of non-specific immune protection (immunoregulatory stimulation, immunoregulatory compensation, immunoregulatory misbalance. The research program was comprehensive.Results. The combined use of Glutargine and Erbisol in the period between exacerbations of psoriatic disease allows to achieve the highest levels of effectiveness, estimated by the integral index (IDCT = 2,28) due to the formation of functional and metabolic compensation in the system of oxidative homoestimulatory state and also the emotional state system of nonspecific immune protection (I = 1.53 ÷ 1.59) with the simultaneous formation of metabolic reserves of patient adaptation. The combined use of Glutargine and Erbisol in the period between exacerbations of chronic eczema allows to achieve the highest levels of efficiency, which are estimated by the integral index (I = 1,71) due to the formation of functional and metabolic compensation in the system of oxidative homeostasis and imunoregulatory stimulation as well as the compensation in non-specific immune protection systems (I = 1.50) with the simultaneous formation of metabolic reserves of patient adaptation.Conclusion. The results of the study indicate the feasibility and effectiveness of using as an antioxidant the drug Glutargine and as an adaptogen - the drug Erbisol. At the same time, ensuring long-term follow-up of patients with psoriatic disease and chronic eczema by GPs-family medicine requires dynamic monitoring of the status of contact-protective systems, in particular oxidative homeostasis and a system of nonspecific immune protection with personification therapy and other therapeutic remedies. It has been determined that while choosing the adaptogenic and antioxidant remedies should be taken into consideration their complex effects.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.